Phthalate draft report
This article was originally published in The Rose Sheet
Executive Summary
The National Toxicology Program Center for the Evaluation of Risks to Human Reproduction is requesting comments on the draft NTP brief on di-(2-ethylhexyl) phthalate. Comments are due July 5, according to a June 5 Federal Register 1notice. The draft brief evaluates the NTP's conclusions on the potential of DEHP to cause reproductive and developmental toxicity, and provides background information on the substance and findings of a CERHR expert panel. Among conclusions in the draft brief, NTP concurs with the expert panel that there is concern with effects on the development of the male reproductive tract for infants under one year of age. After the comment period and upon finalization, the NTP brief for DEHP will be included in the CERHR monograph for DEHP, center notes. NTP requested data on the ingredient last February, in preparation for a fall expert panel meeting (2"The Rose Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip